Broadening eligibility critera for cancer clinical trials will give more patients the opportunity to contribute to scientific research.

ASCO CMO Dr. Richard L. Schilsky invites all cancer researchers to come together for education and networking around cancer clinical trials.

Dr. Arjun Gupta reconsidered an order (and the evidence) for a neutropenic diet when it negatively affected his patient's quality of life.  

As a pragmatic investigator and physician who has witnessed remarkable progress in the treatments we can now offer individuals with cancer, I believe the FDA’s support of more rapid and nimble testing and...

Dr. Edward S. Kim encourages you to register today and join the Research Community Forum in September for 2 days of learning and collaboration.

As the NSABP celebrates its 60th anniversary in 2018, Dr. Harry D. Bear honors the organization's history and accomplishments.

Clinical trials are the pathway to better treatments, better outcomes, and a future without cancer. We, as investigators, need to believe in them, and be willing to offer them to all patients who are eligible....

ASCO's current president explains why he's passionate about precision medicine, as well as the concerns that keep him up at night. 

A trial of aqueous lidocaine to manage painful intercourse for breast cancer survivors was a small study with a great magnitude of benefit. Do we need to wait for more data, or can we start applying these...

Dr. Richard L. Schilsky describes ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) Study and similar independent studies worldwide.